Bioengineering and omics approaches for Type 1 diabetes practical research: advancements and constraints

Area of Science:

• Immunology
• Endocrinology
• Biomedical Engineering

Background:

• Type 1 diabetes (T1D) is an autoimmune disease targeting pancreatic β cells, necessitating lifelong insulin therapy without a cure.
• Current understanding of T1D pathophysiology is insufficient for developing effective clinical treatments and preventing complications.

Purpose of the Study:

• To review recent advancements in pancreatic tissue bioengineering and high-throughput omics analysis for Type 1 diabetes (T1D).
• To discuss the application and limitations of these technologies in understanding and potentially treating T1D.

Main Methods:

• Review of current literature on pancreatic tissue bioengineering models for T1D.
• Analysis of recent progress in high-throughput omics technologies (genomic, molecular) applied to T1D.
• Examination of the integration of bioengineering and omics data in T1D research.

Main Results:

• Pancreatic tissue bioengineering models provide valuable platforms for studying islet function in T1D.
• High-throughput omics analysis has refined the genotypic and molecular profiles of T1D.
• Integrating these advanced techniques offers a more comprehensive view of T1D.

Conclusions:

• Further research utilizing bioengineered models and omics data is crucial for advancing T1D treatment strategies.
• Addressing the translational gap requires a deeper understanding of T1D pathophysiology informed by these innovative approaches.
• These technologies hold promise for developing novel therapeutic interventions for Type 1 diabetes.